Payment overview · 2025
General Payments
$432.71
7 reported records · 3 companies
Healthcare provider profile · identity verified
David Harrison, DO
Allopathic & Osteopathic Physicians|Family Medicine · ANKENY, IA · NPI 1033128418
Verified facts
What the public records show
CMS Open Payments records show David Harrison, DO received $432.71 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 70.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $305.48 | 70.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.34 | 26.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.89 | 3.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $413.86 | 6 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.47 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $83.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.89 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 230 |
| Omeprazole | Omeprazole | 534 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 92 |
| Alprazolam | Alprazolam | 302 | 54 |
| Simvastatin | Simvastatin | 297 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 59 |
| Losartan Potassium | Losartan Potassium | 274 | 78 |
| Lisinopril | Lisinopril | 264 | 76 |
| Sertraline Hcl | Sertraline Hcl | 245 | 65 |
| Metformin Hcl Er | Metformin Hcl | 241 | 63 |
| Gabapentin | Gabapentin | 237 | 58 |
| Tramadol Hcl | Tramadol Hcl | 232 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 34 |
| Metformin Hcl | Metformin Hcl | 163 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 40 |
| Meloxicam | Meloxicam | 156 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 44 |
| Warfarin Sodium | Warfarin Sodium | 152 | 24 |
| Furosemide | Furosemide | 148 | 51 |
| Eliquis | Apixaban | 147 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 36 |
| Glipizide Er | Glipizide | 124 | 34 |
| Trazodone Hcl | Trazodone Hcl | 118 | 29 |
| Allopurinol | Allopurinol | 117 | 32 |
| Jardiance | Empagliflozin | 114 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 32 |
| Pregabalin | Pregabalin | 99 | 19 |
| Montelukast Sodium | Montelukast Sodium | 93 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 28 |
| Prednisone | Prednisone | 89 | 39 |
| Ozempic | Semaglutide | 88 | 16 |
| Finasteride | Finasteride | 87 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 30 |
| Lorazepam | Lorazepam | 86 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 78 | 21 |
| Trulicity | Dulaglutide | 78 | suppressed |
| Azithromycin | Azithromycin | 77 | 60 |
| Benazepril Hcl | Benazepril Hcl | 76 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Ondansetron Odt | Ondansetron | 63 | suppressed |
| Clonazepam | Clonazepam | 62 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 17 |
| Ezetimibe | Ezetimibe | 59 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 20 |
| Donepezil Hcl | Donepezil Hcl | 58 | 19 |
| Mirtazapine | Mirtazapine | 57 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 46 |
| Spironolactone | Spironolactone | 54 | 18 |
| Alendronate Sodium | Alendronate Sodium | 53 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 14 |
| Celecoxib | Celecoxib | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 15 |
| Baclofen | Baclofen | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Glipizide | Glipizide | 46 | 11 |
| Glimepiride | Glimepiride | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 32 |
| Cephalexin | Cephalexin | 40 | 25 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 19 |
| Dilt-Xr | Diltiazem Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 25 | 11 |
| Nystatin | Nystatin | 25 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 12 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.71 · 7 records | Novo Nordisk Inc | JARDIANCE, Ozempic, VOQUEZNA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error